If your institution subscribes to this resource, and you don't have an Access Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.
Download the Access App here: iOS and Android. Learn more here!
Truxima16,165-167,*,#
CD20-directed monoclonal antibody
Biosimilar [not interchangeable] for rituximab (Rituxan);168 also similar to obinutuzumab and ocrelizumab (for multiple sclerosis), ofatumumab (for chronic lymphocytic leukemia)
Non-Hodgkin’s lymphoma†
Chapter 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules > CD20 Inhibitors
eChapter 2018 Part 2: The Goodman & Gilman Year in Review: 2018 New and Noteworthy FDA Approvals